The DOI matches its OpenAlex record; 43 of the 43 references it cites were found in a registry or an index.
Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors
Abstract
PURPOSE: To investigate the feasibility and pharmacokinetics of the combination cisplatin, gemcitabine, and SU5416. PATIENTS AND METHODS: Patients received cisplatin 80 mg/m(2) on day 1, gemcitabine 1,250 mg/m(2) on days 1 and 8, repeated every 3 weeks, and SU5416 (85 and 145 mg/m(2)) intravenously twice weekly. Pharmacokinetics of all three agents, side effects, and antitumor response were investigated in patients with solid tumors amenable to therapy with cisplatin/gemcitabine. RESULTS: In the first cohort of three patients entered at the 85 mg/m(2) dose, no dose-limiting toxicities were observed. In the next cohort (145 mg/m(2)), three patients developed a thromboembolic event. After entry was restricted to patients with low thromboembolic risk, three additional patients enrolled at 145 mg/m(2) developed a thromboembolic event. The dose was then reduced to 85 mg/m(2) in all patients still on the study, and three additional patients were entered on this dose level. In 19 treated patients, eight patients developed nine thromboembolic events (three transient ischemic attacks, two cerebrovascular accidents, and four deep venous thromboses). The most common toxicities observed were those previously reported for SU5416 alone (headache and phlebitis) and for this chemotherapy regimen (nausea, thrombocytopenia, and leucopenia). No significant pharmacologic interaction among the three drugs was observed. Response rates were similar to those expected in the patient population selected for this study. Analysis of variables of the coagulation cascade and of vessel wall activation was performed in three patients and showed significant increases in thrombin generation and endothelial cell perturbation in a treatment cycle-dependent manner. CONCLUSION: The incidence of thromboembolic events, possibly related to the particular regimen tested in this study, discourages further investigation of this regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,839
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
Cines, D. B., Pollak, E. S., Buck, C. A., Loscalzo, J., Zimmerman, G. A., McEver, R. P., Pober, J. S., Wick, T. M., Konkle, B. A., Schwartz, B. S., et al. (1998) · PubMed · doi:10.1182/blood.v91.10.3527 · Cited by 2,256
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,109
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_6 · Cited by 743
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
Hood, J. D., Meininger, C. J., Ziche, M., & Granger, H. J. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.3.h1054 · Cited by 699
Pepper, M. S., Ferrara, N., Orci, L., & Montesano, R. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91276-i · Cited by 615
Vascular-Bed–Specific Hemostasis and Hypercoagulable States
Rosenberg, R. D., & Aird, W. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905203402007 · Cited by 569
Cardenal, F., López-Cabrerizo, M. P., Antón, A., Alberola, V., Massuti, B., Carrato, A., Barneto, I., Lomas, M., García, M., Lianes, P., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.12 · Cited by 471
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer
Levine, M. N., Gent, M., Hirsh, J., Arnold, A., Goodyear, M. D., Hryniuk, W., & De Pauw, S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802183180703 · Cited by 412
Seo, Y., Baba, H., Fukuda, T., Takashima, M., & Sugimachi, K. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000515)88:10<2239::aid-cncr6>3.0.co;2-v · Cited by 400
Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D. J., McMahon, G., & Ellis, L. M. (1999) · PubMed · Cited by 334
Brock, T. A., Dvorak, H. F., & Senger, D. R. (1991) · PubMed · Cited by 321
Abe, K., Shoji, M., Chen, J., Bierhaus, A., Danave, I., Micko, C., Casper, K., Dillehay, D. L., Nawroth, P. P., & Rickles, F. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8663 · Cited by 312
Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman, A. M., van Haperen, V. W. T. R., Veerman, G., Kuiper, C. M., & Peters, G. J. (1996) · PubMed · Cited by 304
Self-citationCisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Crinò, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.297 · Cited by 303
Shen, B.-Q., Lee, D. Y., & Zioncheck, T. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.33057 · Cited by 286
Neurological complications of radiotherapy and chemotherapy
Keime-Guibert, F., Napolitano, M., & Delattre, J.-Y. (1998) · Journal of Neurology · doi:10.1007/s004150050271 · Cited by 246
Mendel, D. B., Laird, A., Smolich, B. D., Blake, R., Liang, C., Hannah, A. L., Shaheen, R. M., Ellis, L. M., Weitman, S., Shawver, L. K., et al. (2000) · PubMed · Cited by 230
DOLL, D. C., LIST, A. F., GRECO, F. A., HAINSWORTH, J. D., HANDE, K. R., & JOHNSON, D. H. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-48 · Cited by 225
Lensing, A. W., Prandoni, P., Prins, M. H., & Büller, H. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04298-6 · Cited by 225
Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents
Levitzki, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00066-7 · Cited by 214
Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications
Ellis, L. M. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-11 · Cited by 196
Moorsel, C. J. A. V., Pinedo, H. M., Veerman, G., Bergman, A. M., Kuiper, C. M., Vermorken, J. B., van der Vijgh, W. J. F., & Peters, G. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690452 · Cited by 192
Self-citationMandriota, S. J., & Pepper, M. S. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.18.2293 · Cited by 187
Shih, C.-H., Ozawa, S., Ando, N., Ueda, M., & Kitajima, M. (2000) · PubMed · Cited by 164
Stopeck, A., Sheldon, M., Vahedian, M., Cropp, G. F., Gosalia, R., & Hannah, A. L. (2002) · PubMed · Cited by 150
Self-citationPoorter, R. L., Lauw, F. N., Bemelman, W. A., Bakker, P. J. M., Taat, C. W., & Veenhof, C. H. N. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00274-2 · Cited by 122
Angiogenesis in Malignancies of the Female Genital Tract
Abulafia, O., Triest, W. E., & Sherer, D. M. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5152 · Cited by 113
Burstein, H. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.693 · Cited by 110
van Moorsel, C. J. A., Kroep, J. R., Pinedo, H. M., Veerman, G., Voorn, D. A., Postmus, P. E., Vermorken, J. B., van Groeningen, C. J., van der Vijgh, W. J. F., & Peters, G. J. (1999) · Annals of Oncology · doi:10.1023/a:1008301522349 · Cited by 107
Self-citationVEGF nuclear accumulation correlates with phenotypical changes in endothelial cells
Li, W., & Keller, G. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.9.1525 · Cited by 85
Evaluation of an Implantable Venous Access System in a General Oncology Population
Barrios, C. H., Zuke, J. E., Blaes, B., Hirsch, J. D., & Lyss, A. P. (2009) · Oncology · doi:10.1159/000227095 · Cited by 68
Takanami, I., Tanaka, F., Hashizume, T., & Kodaira, S. (1997) · PubMed · Cited by 67
Thrombomodulin-Dependent Anticoagulant Activity Is Regulated by Vascular Endothelial Growth Factor
Calnek, D. S., & Grinnell, B. W. (1998) · Experimental Cell Research · doi:10.1006/excr.1997.3812 · Cited by 59
Angiogenesis as a biologic and prognostic indicator in human breast carcinoma
Engels, K., Fox, S. B., & Harris, A. L. (1997) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-9006-9_6 · Cited by 27
Cited by
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00379.x · Cited by 744
Venous Thromboembolism and Cancer: Risks and Outcomes
Lee, A. Y. Y., & Levine, M. N. (2003) · Circulation · doi:10.1161/01.cir.0000078466.72504.ac · Cited by 721
The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
Rathbun, S. (2009) · Circulation · doi:10.1161/circulationaha.108.841403 · Cited by 575
Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503
Self-citation
Metadata
- Authors
- Kuenen, B. C., Rosen, L. S., Smit, E. F., Parson, M., Levi, M. M., Ruijter, R., Huisman, H., Kedde, M. A., Noordhuis, P., van der Vijgh, W. J. F., Peters, G. J., Cropp, G. F., Scigalla, P., Hoekman, K., Pinedo, H. M., & Giaccone, G.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-03-15
- Volume
- 20
- Issue
- 6
- Pages
- 1657-1667
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2096345747
- Cited by
- 279
- References
- 43
- FWCI
- 16.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.